A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM).

Trial Profile

A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Fresolimumab (Primary)
  • Indications Mesothelioma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top